China is the world's second-largest drug producer but has traditionally focused on domestic commercialization. Today, that is changing. Nearly half of all new drug molecules in human trials worldwide now originate from China, and Morgan Stanley projects annual revenue from Chinese-originated drugs could reach $34 billion by 2030 and $220 billion by 2040. Due to recent policy changes that open new opportunity for China, it is expected to become a major hub for licensing deals for international commercialization. But before the 'sleeping giant' can awaken, it needs regulatory and, sometimes, clinical development support in local markets.

Veristat provides Chinese drug and device companies with trusted regulatory services to bring novel therapies already approved domestically through regional regulatory pathways for approval across Europe, the UK, Switzerland, the US, Canada, and Australia. The American-based CRO has extensive experience preparing, submitting, and obtaining approvals for Marketing Authorization Applications (MAA) and New Drug Applications (NDAs), often based largely on foreign data. Veristat can also serve as the applicant to enable companies without a legal presence in these regions to quickly and efficiently submit their regulatory dossiers.

"Veristat has the deep understanding of the regulatory landscape needed to support foreign organizations with entry to key markets. Our team really enjoyed working with the Veristat team, as they always supported with prompt responses, flexibility, and recommendations on problem-solving," said Li Zhang, Regulatory Affairs at CStone Pharmaceuticals.

Veristat's multidisciplinary team conducts a thorough Gap Analysis of each customer's data package, recommends the most efficient regulatory strategy, and guides the best path to approval across countries. This includes identifying and generating any additional analyses required, as well as compiling or developing the necessary data for submission to the relevant agencies. For instance, Veristat offers comprehensive clinical trial execution support for foreign companies whose domestic clinical trial data is not sufficient for local regulatory requirements.

"Veristat has had tremendous success for China-based customers recently, securing approvals in the US, EU, and UK. These successes were achieved through comprehensive dossier development and effective negotiations with EMA, MHRA, and FDA," explained Daphne Smyth, Vice President of Global Regulatory Affairs at Veristat. "We also support subsequent submissions in Canada, Switzerland, Australia, and other regions globally, and provide comprehensive assistance throughout the entire agency review process."

Between 2020 and 2025, Veristat submitted 68 initial INDs and DMFs, 10 initial Food and Drug Administration (FDA) marketing applications, and 8 initial EMA/MHRA/Swissmedic marketing applications. With 30 years of supporting more than 100 regulatory approvals, the full-service CRO has deep experience in rare disease, neurological disease, oncology, and advanced medicines including cell and gene therapies.

Veristat will be attendingBIO China(March 12-14) and CMAC (March 18-20) both in Suzhou, China, where companies can learn more about its international service offering. Email[email protected]to arrange a meeting.

About Veristat

Veristat is a full-service CRO and consultancy that helps life sciences companies bring novel therapies to market fast. With 30 years of experience and support in more than 100 regulatory approvals and deep expertise in rare disease, neurological disease, oncology, and advanced therapies, Veristat integrates strategic planning, regulatory insight, and trial execution to overcome complex challenges and accelerate success. From early planning through approval, Veristat delivers tailored solutions that drive meaningful outcomes for patients worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311570116/en/

Contact

Media:Lisa Barbadora, Barbadora INK for Veristat+1 (610) 420-3413[email protected]

© 2026 Business Wire, Inc.Disclaimer:This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.